Metacrine, Inc (MTCR)

Etorro trading 970x250

About Metacrine, Inc

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Address: 3985 Sorrento Valley Boulevard, San Diego, CA, United States, 92121

Metacrine, Inc News and around…

Latest news about Metacrine, Inc (MTCR) common stock and company :

Metacrine Reports First-Quarter 2022 Results
12 May, 2022 Yahoo! Finance

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its first-quarter 2022 financial results and provided a business update. Metacrine announced today that it has engaged a strategic financial advisor and initiated a review of strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be ex

Overview Of Value Stocks In The Healthcare Sector
04 Apr, 2022 FinancialContent

The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ...

Metacrine Reports Fourth-Quarter 2021 Results
30 Mar, 2022 Yahoo! Finance

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its fourth-quarter 2021 financial results. “We continue to devote all of our development effort to bringing expanded therapeutic options to people living with ulcerative colitis (UC),” said Preston Klassen, M.D., MHS, CEO, Metacrine. “We have generated preclinical data that supports

Metacrine Announces Executive Leadership Changes
24 Feb, 2022 Yahoo! Finance

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today announced that Ms. Trisha Millican has resigned her position as chief financial officer. Ms. Millican will remain with the Company until March 31, 2022 to ensure a smooth transition. In addition, Mr. Michael York, currently senior vice president, business development and commercial strategy, h

Metacrine To Slash Its Workforce By 50%
11 Feb, 2022 FinancialContent

Metacrine Inc(NASDAQ: MTCR) will ax half of its staff to conserve cash as it makes a last-stand drug development effort. Its ...

Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan
11 Feb, 2022 Yahoo! Finance

U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitisSufficient capital to complete Phase 2 IBD trial SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that it remains on track to begin a Phase 2 clinical trial in ulcerative colitis. Metacrine has received authorization from the U.S. Food and Drug

12 Health Care Stocks Moving In Monday's Pre-Market Session
07 Feb, 2022 FinancialContent

Gainers Enveric Biosciences (NASDAQ:ENVB) shares increased by 12.9% to $0.7 during Monday's pre-market session. The ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
01 Feb, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine, trader! We're starting off another day of investing with a breakdown of the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

26 Stocks Moving in Thursday's Pre-Market Session
27 Jan, 2022 FinancialContent

Gainers The National Security Group, Inc.(NASDAQ: NSEC) rose 63.7% to $15.10 in pre-market trading after VR ...

Stocks That Hit 52-Week Lows On Friday
07 Jan, 2022 FinancialContent

Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana ...

Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
29 Dec, 2021 FinancialContent

Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current "challenging" operating environment.

51 Biggest Movers From Yesterday
28 Dec, 2021 FinancialContent

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a ...

5 Value Stocks In The Healthcare Sector
27 Dec, 2021 FinancialContent

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ...

Metacrine Announces Resignation of Chief Medical Officer
27 Dec, 2021 Yahoo! Finance

SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity. Dr. Chen’s resignation is effective December 31, 2021. Preston Klassen, M.D., MHS, chief executive officer, is expected to assume responsibility for Metacrine’s ongoing clinical tria

Is the Options Market Predicting a Spike in Metacrine (MTCR) Stock?
20 Dec, 2021 Yahoo! Finance

Investors need to pay close attention to Metacrine (MTCR) stock based on the movements in the options market lately.

63 Biggest Movers From Friday
20 Dec, 2021 FinancialContent

Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on ...

Metacrine Reports Third-Quarter 2021 Results
11 Nov, 2021 Yahoo! Finance

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today reported its third-quarter 2021 financial results. “Our recent monotherapy and combination trial results demonstrate the strong therapeutic profile of our FXR program in non-alcoholic steatohepatitis (NASH), while also highlighting the potential of these agents as an important part o

Metacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients
02 Nov, 2021 FinancialContent

Metacrine Inc(NASDAQ: MTCR)reported topline resultsfrom its Phase 2a trial of MET409 in combination withEli ...

Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
02 Nov, 2021 Yahoo! Finance

- Validates therapeutic benefit of combination approaches for a large segment of NASH patients- Demonstrates additive efficacy results and favorable tolerability profile SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today reported topline results from its Phase 2a trial evaluating MET409, a farnesoid X receptor (FXR) agonist, in combi

How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More
25 Oct, 2021 FinancialContent

Last week, the five biggest stock market losers declined between about 75% and 37%. Below is a look at each stock and what they may have ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
25 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! We're kicking off another busy week of trading with lists of the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

55 Biggest Movers From Friday
25 Oct, 2021 FinancialContent

Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on ...

Mid-Afternoon Market Update: Nasdaq Down 70 Points; Ocular Therapeutix Shares Drop
22 Oct, 2021 FinancialContent

Toward the end of trading Friday, the Dow traded up 0.23% to 35,685.44 while the NASDAQ fell 0.46% to 15,145.51. The S&P also fell, ...

Mid-Day Market Update: Snap Drops After Q3 Results; Creatd Shares Jump
22 Oct, 2021 FinancialContent

Midway through trading Friday, the Dow traded up 0.25% to 35,690.68 while the NASDAQ fell 0.46% to 15,145.78. The S&P also rose, ...

35 Stocks Moving In Friday's Mid-Day Session
22 Oct, 2021 FinancialContent

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with ...

26 Stocks Moving in Friday's Pre-Market Session
22 Oct, 2021 FinancialContent

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 300% to $6.10 in pre-market trading. Phunware shares jumped over 45% on Thursday, ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
22 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Happy Friday, trader! The week's almost done and we're starting off the final day of it with a look at the biggest pre-market stock movers! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs
21 Oct, 2021 Yahoo! Finance

SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today reported interim results from a Phase 2a clinical trial evaluating the efficacy and safety of MET642, a farnesoid X receptor (FXR) agonist, in approximately 60 non-alcoholic steatohepatitis (NASH) patients after 16 weeks of treatment. The Company also announced it is prioritizing its

Implied VTI Analyst Target Price: $255
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Total Stock Market ETF (VTI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $255.38 per unit.

48 Biggest Movers From Friday
27 Sep, 2021 FinancialContent

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday. Clearwater Analytics Holdings, ...

Metacrine, Inc (MTCR) is a NASDAQ Common Stock listed in , ,

970x250